Investigational drug · Phase 2
YH42946
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NSCLC (Non-small Cell Lung Cancer), Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "YH42946"
First trial start
2024
Oct 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YH42946", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC (Non-small Cell Lung Cancer)
- Solid Tumor
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "YH42946" as an intervention, largest first.
Yuhan CorporationIndustry
NCT06616766 · 201 participants (planned) · Start Oct 2, 2024 · Primary completion Mar 15, 2028
Drug: YH42946 · For: NSCLC (Non-small Cell Lung Cancer); Solid Tumor
Sites: Fairfax, Virginia; Seongnam-si, South Korea; Suwon, South Korea · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for NSCLC (Non-small Cell Lung Cancer)
- AndamertinibPLB1004Phase 38 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
- OSE2101Phase 32 trials
OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma
- SugemalimabPhase 32 trials
Akeso · NSCLC (Non-small Cell Lung Cancer), Extranodal NK/T-cell Lymphoma
- JMKX001899Phase 31 trial
Jemincare · NSCLC (Non-small Cell Lung Cancer)
- IAM1363Phase 21 trial
Iambic Therapeutics, Inc · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer
- OSE-279Phase 21 trial
OSE Immunotherapeutics · Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)
- TXN10128Phase 21 trial
Txinno Bioscience Inc. · NSCLC (Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.